Togami, Katsuhiro <br/><br/>
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.  [electronic resource] 

 -  The Journal of clinical investigation  11 2019 
 - 5005-5019 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1558-8238 
<br/><br/><label>Standard No.: </label>10.1172/JCI128571  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Azacitidine--pharmacology<br/>Cell Line, Tumor<br/>DNA Methylation<br/>Dendritic Cells--metabolism<br/>Drug Delivery Systems<br/>Female<br/>Hematologic Neoplasms--drug therapy<br/>Humans<br/>Interleukin-3 Receptor alpha Subunit--metabolism<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Mice<br/>Mice, Nude<br/>Minor Histocompatibility Antigens--metabolism<br/>Neoplasm Proteins--metabolism<br/>Recombinant Fusion Proteins--pharmacology<br/>Tumor Suppressor Proteins--metabolism<br/>Xenograft Model Antitumor Assays